Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIBA versus insulin glargine added to oral antidiabetic drugs in type 2 diabetes
2008-005776-27Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing SIBA + oral antidiabetic drugs with Insulin glargine + oral antidiabetic drugs (2 arms). Primary endpoint: Change from baseline in HbA1c after 52 weeks of treatment. Started Apr 2009; status: completed.
02
Drugs
insulin degludecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-005776-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005776-27.